# EDGAR Filing Document

**Accession Number:** 0001760854
**File Stem:** 0001171843-26-003603
**Filing Date:** 2026-5
**Character Count:** 6038
**Document Hash:** 5f08077b0bbdec48f8c42cc5f1480225
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-003603.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0001171843-26-003603

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260521

**FILED AS OF DATE**: 20260521

**DATE AS OF CHANGE**: 20260521

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nanobiotix S.A.
- **CENTRAL INDEX KEY:** 0001760854
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39777
- **FILM NUMBER:** 261006190

**BUSINESS ADDRESS:**
- **STREET 1:** 60 RUE DE WATTIGNIES
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75012
- **BUSINESS PHONE:** 33140260470

**MAIL ADDRESS:**
- **STREET 1:** 60 RUE DE WATTIGNIES
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of May 2026**

Commission File Number: **001-39777**

**Nanobiotix S.A.**

(Translation of registrant's name into English)

**60 Rue de Wattignies 75012 Paris, France**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

------

On May 21, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[(c) Exhibit 99.1. Press release dated May 21, 2026](exh_991.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;Nanobiotix S.A.&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: May 21, 2026 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Bart Van Rhijn&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Bart Van Rhijn |
|  | Chief Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris**

PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – "**Nanobiotix**" or the "**Company**"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. (Paris time) / 9:30 a.m. (New York time).

Trading of the ordinary shares of the Company was halted at the request of the Company on May 21, 2026 from 9:00 a.m. CEST in the context of the previously announced offering consisting of (i) a public offering of its American Depositary Shares ("**ADSs**"), each ADS representing one ordinary share, €0.03 nominal value per share (each an "**Ordinary Share**"), of the Company, in the United States (the "**U.S. Offering**") and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to "qualified investors" in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and certain other countries (excluding the United States and Canada) (the "**International Offering**" and, together with the U.S. Offering, the "**Global Offering**"), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Global Offering.

**About NANOBIOTIX**

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States), amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

**Contacts**

---

| | |
|:---|:---|
| *Nanobiotix* | *Nanobiotix* |
| <br>**Communications <br>Department**<br>*Brandon Owens*<br>*VP, Communications*<br>+1 (617) 852-4835<br><u>contact@nanobiotix.com</u><br>| <br>**Investor Relations Department** <br>*Joanne Choi*<br>*VP, Investor Relations (US)*<br>*+1 (713) 609-3150*<br>*Ricky Bhajun*<br>*Director, Investor Relations (EU)*<br>*investors@nanobiotix.com* |
| *Media Relations* | *Media Relations* |
| <br>France – **HARDY**<br>Caroline Hardy<br>+ 33 06 70 33 49 50 <br>carolinehardy@outlook.fr | <br>Global – **uncapped Communications**<br>Becky Lauer<br>+1 (646) 286-0057<br>uncappednanobiotix@uncappedcommunications.com |

---

**Disclaimers**

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

**Attachment**

* 2026-05-21 -- NBTX -- Trading Resumes -- FINAL (https://ml.globenewswire.com/Resource/Download/1c86357a-3aa0-4139-bc5d-8f7de523db93)